Buffett's Successor Dumps UnitedHealth as Stock Surges 40%—Strategic Pivot or Missed Call?

Greg Abel, the newly appointed CEO of Berkshire Hathaway, made a bold portfolio move in the first quarter of 2026, completely liquidating the conglomerate's entire 5.1 million-share position in UnitedHealth Group—one of the nation's largest health insurance companies. The decision, part of what appears to be a systematic portfolio restructuring, has drawn scrutiny as UnitedHealth ($UNH) shares have climbed more than 40% since the sale. Yet despite the impressive subsequent rally, defenders of Abel's decision argue the move reflects disciplined risk management rather than a strategic misstep, pointing to underlying valuation concerns and persistent operational headwinds at the healthcare giant.

The stock sale marks a significant moment in the transition to Abel's leadership at Berkshire Hathaway ($BRK.B), signaling potential shifts in the company's investment philosophy under the 63-year-old executive who rose through the ranks of Berkshire's insurance and energy operations. The move wasn't made in isolation—Berkshire simultaneously exited positions in Amazon, Domino's Pizza, Mastercard, and Visa during the same quarter, while strategically expanding its holdings in Alphabet and deploying fresh capital into new positions including Delta Airlines and Macy's.

Key Details: A Portfolio Reshuffling

The divestment from UnitedHealth represents a complete exit from a healthcare insurance position that Berkshire had maintained for years. The company sold all 5.1 million shares, a substantial move for an investor of Berkshire's scale. The timing—in Q1 2026—placed the sale before the subsequent rally that would ultimately see the stock appreciate by more than 40% in the months that followed.

Berkshire's Q1 2026 portfolio activity extended well beyond the healthcare sector:

• Exited positions: UnitedHealth Group, Amazon ($AMZN), Domino's Pizza, Mastercard ($MA), and Visa ($V)
• Increased stakes: Alphabet ($GOOGL)
• New investments: Delta Airlines and Macy's

The breadth of these changes suggests Abel and his investment team conducted a comprehensive review of the portfolio inherited from Warren Buffett, who stepped back from day-to-day operations but remains as Chairman. This "spring cleaning" approach—selling positions deemed overvalued or problematic while reinforcing conviction bets—has long been part of Berkshire's investment philosophy, though the scale of exits in Q1 2026 was noteworthy.

Market Context: Valuation Concerns Amid Healthcare Uncertainty

Understanding Abel's UnitedHealth decision requires context on both the healthcare insurance industry and the specific challenges facing the company. UnitedHealth Group, America's largest health insurer by revenue, had faced mounting pressure from multiple directions heading into 2026.

The healthcare insurance sector has endured significant turbulence in recent years. Rising medical costs, particularly in specialty pharmaceuticals and outpatient care, have squeezed margins across the industry. UnitedHealth specifically had been grappling with:

• Medical cost inflation exceeding premium growth in certain segments
• Regulatory scrutiny over prior authorization practices and claim denials
• Operational complexity from its vast portfolio spanning health insurance, pharmacy benefits management, and healthcare services
• Integration challenges from past acquisitions that required ongoing attention

At the time of Berkshire's sale, UnitedHealth shares had already experienced meaningful appreciation from pandemic lows, and the valuation—measured against forward earnings and free cash flow—had reached levels that prudent value investors often view with caution. The stock's price-to-earnings multiple had expanded significantly, leaving limited margin for error should the company face unexpected headwinds.

This context matters because Berkshire's investment philosophy, particularly under Buffett, has long emphasized buying quality assets at reasonable prices and maintaining patience. When valuations stretch, the appropriate action—even if that company later rallies further—is often to take profits. The 40% gain since the sale, while impressive in absolute terms, doesn't necessarily validate holding through periods of elevated valuation risk.

Meanwhile, Berkshire's decision to increase Alphabet exposure and deploy capital into Delta and Macy's—both turnaround stories in their respective sectors—signals a willingness to take more concentrated bets on value opportunities. This reallocation suggests Abel's team identified more compelling risk-reward opportunities elsewhere in the market.

Investor Implications: What This Teaches Us About Portfolio Management

For Berkshire Hathaway shareholders, the UnitedHealth exit and broader Q1 2026 portfolio reshuffling carries several important lessons:

The Timing Question: While missing a 40% rally stings in hindsight, investors should recognize that perfect market timing is impossible. Berkshire's decision to exit at a higher valuation—before subsequent gains—may prove prudent if UnitedHealth faces disappointments or if the broader market experiences volatility. Many investors who sold Apple shares in 2008 to buy Coca-Cola missed a spectacular rally but made portfolio decisions that were rational at the time.

Valuation Discipline: Abel's willingness to exit a "quality" company like UnitedHealth underscores that no investment is a permanent holding. When valuations become stretched relative to intrinsic value, even the best-run companies warrant selling. This discipline separates opportunistic traders from long-term wealth builders.

Capital Allocation Flexibility: By trimming positions in mature, highly-valued franchises (Amazon, Visa, Mastercard) while backing different opportunities (Alphabet, Delta, Macy's), Abel demonstrates that he's not simply running a "hold everything forever" strategy. This willingness to actively reshape the portfolio could generate significant long-term returns if the new positions outperform.

Succession Credibility: The sheer scale of portfolio changes sends a message to Berkshire shareholders: Abel is not merely maintaining Buffett's legacy but actively managing the business with his own conviction. This matters for investor confidence in the leadership transition.

For the broader market, Berkshire's moves signal that even legendary investors believe certain highly-valued stocks warrant caution. When a portfolio manager with Berkshire's resources and sophistication exits a position entirely, it's worth noting—not as a definitive contrarian signal, but as evidence that valuations matter in long-term investing.

Looking Forward: The Abel Era at Berkshire

As Greg Abel fully assumes command of Berkshire Hathaway, his Q1 2026 portfolio decisions will face ongoing scrutiny. The UnitedHealth exit will be referenced regularly if the stock continues rallying—and perhaps vindicated if the company stumbles. This is the nature of investment management: some decisions prove prophetic while others cost billions in foregone gains.

What matters most is whether Abel's overall portfolio management—including the exits, the increased Alphabet position, and the new bets on Delta and Macy's—generates superior long-term returns compared to Buffett's approach. One quarter of data points in only one direction. The real test of Abel's stewardship will unfold over years, not months.

For investors watching Berkshire Hathaway, the lesson is clear: even legendary investors sometimes sell winners that subsequently rally further. The question isn't whether Abel perfectly timed the UnitedHealth exit—he didn't. The question is whether his disciplined approach to valuation, capital allocation, and portfolio construction will ultimately generate the exceptional long-term returns that made Berkshire legendary in the first place.